Eddy Kinganda - Lusamaki

Dr. Eddy Kinganda - Lusamaki

IRD, TransVIHMI, University of Montpellier, Montpellier, Occitanie, France
+2
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
EVEmmanuel Hasivirwe Vakaniaki
Emmanuel Hasivirwe Vakaniaki
CKCris Kacita
Cris Kacita
ELEddy Kinganda - Lusamaki
Eddy Kinganda - Lusamaki
ÁOÁine O’tOole
Áine O’tOole
TWTony Wawina-Bokalanga
Tony Wawina-Bokalanga
PMPlacide Kingebeni Mbala
Placide Kingebeni Mbala
Outbreaks of monkeypox (mpox) have historically resulted from zoonotic spillover of clade I monkeypox virus (MPXV) in Central Africa and clade II MPXV in West Africa. In 2022, subclade IIb caused a global epidemic linked to transmission through sexual contact. Here we describe the epidemiological and genomic features of an mpox outbreak in a mining region in eastern Democratic Republic of the Congo, caused by clade I MPXV. Surveillance data collected between September 2023 and January 2024 identified 241 suspected cases. Genomic analysis demonstrates a distinct clade I lineage divergent from previously circulating strains in the Democratic Republic of the Congo. Of the 108 polymerase chain reaction-confirmed mpox cases, the median age of individuals was 22 years, 51.9% were female and 29% were sex workers, suggesting a potential role for sexual transmission. The predominance of APOBEC3-type mutations and the estimated emergence time around mid-September 2023 imply recent sustained human-to-human transmission.

7 October 2022 in Science
Verified
Journal Article
Closed access
HTHouriiyah Tegally
Houriiyah Tegally
JSJames Emmanuel San
James Emmanuel San
MCMatthew Cotten
Matthew Cotten
MMMonika Moir
Monika Moir
BTBryan Tegomoh
Bryan Tegomoh
EWEduan Wilkinson
Eduan Wilkinson
Investment in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing in Africa over the past year has led to a major increase in the number of sequences that have been generated and used to track the pandemic on the continent, a number that now exceeds 100,000 genomes. Our results show an increase in the number of African countries that are able to sequence domestically and highlight that local sequencing enables faster turnaround times and more-regular routine surveillance. Despite limitations of low testing proportions, findings from this genomic surveillance study underscore the heterogeneous nature of the pandemic and illuminate the distinct dispersal dynamics of variants of concern—particularly Alpha, Beta, Delta, and Omicron—on the continent. Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve while the continent faces many emerging and reemerging infectious disease threats. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century.

22 October 2021 in Science
Verified
Journal Article
Open access
EWEduan Wilkinson
Eduan Wilkinson
Marta GiovanettiMarta Giovanetti
Marta Giovanetti
HTHouriiyah Tegally
Houriiyah Tegally
JSJames Emmanuel San
James Emmanuel San
RLRichard Lessells
Richard Lessells
TOTulio De Oliveira
Tulio De Oliveira
SARS-CoV-2 across Africa: The impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been hard to track in African countries, largely because of patchy data. Wilkinson et al . curated viral genomes collected in 2021 from several countries across the continent. Outbreaks during 2020 in each African country were initiated by imported cases, mostly from Europe. As the pandemic developed, case numbers in African countries were likely many times higher than reported, and subsequent waves of the pandemic appear to have been more severe. Consequently, high-transmission variants have emerged that have spread within the continent, and African countries must be included in global control efforts. —CA

24 October 2024 in Cell
Verified
Journal Article
Open access
ELEddy Kinganda - Lusamaki
Eddy Kinganda - Lusamaki
AAAdrienne Amuri-Aziza
Adrienne Amuri-Aziza
NFNicolas Fernandez-Nuñez
Nicolas Fernandez-Nuñez
JMJean-Claude Makangara-Cigolo
Jean-Claude Makangara-Cigolo
CPCatherine Pratt
Catherine Pratt
SMSteve Ahuka Mundeke
Steve Ahuka Mundeke
Recent reports raise concerns on the changing epidemiology of mpox in the Democratic Republic of the Congo (DRC). High-quality genomes were generated for 337 patients from 14/26 provinces to document whether the increase in number of cases is due to zoonotic spillover events or viral evolution, with enrichment of APOBEC3 mutations linked to human adaptation. Our study highlights two patterns of transmission contributing to the source of human cases. All new sequences from the eastern South Kivu province (n = 17; 4.8%) corresponded to the recently described clade Ib, associated with sexual contact and sustained human-to-human transmission. By contrast, all other genomes are clade Ia, which exhibits high genetic diversity with low numbers of APOBEC3 mutations compared with clade Ib, suggesting multiple zoonotic introductions. The presence of multiple clade I variants in urban areas highlights the need for coordinated international response efforts and more studies on the transmission and the reservoir of mpox.

1 April 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PMPlacide Kingebeni Mbala
Placide Kingebeni Mbala
CPCatherine Pratt
Catherine Pratt
MMMbusa Mutafali-Ruffin
Mbusa Mutafali-Ruffin
MPMatthias G. Pauthner
Matthias G. Pauthner
FBFaustin Bile
Faustin Bile
JTJean-Jacques Muyembe Tamfum
Jean-Jacques Muyembe Tamfum
During the 2018–2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus–based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)–specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.)

12 April 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ELEddy Kinganda - Lusamaki
Eddy Kinganda - Lusamaki
ABAllison Black
Allison Black
DMDaniel B. Mukadi
Daniel B. Mukadi
JHJames Hadfield
James Hadfield
PMPlacide Mbala-Kingebeni
Placide Mbala-Kingebeni
JTJean-Jacques Muyembe Tamfum
Jean-Jacques Muyembe Tamfum